Phase 2 N=22 Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
Melanoma
Primary: Number of Participants With Dose-limiting Toxicities. — 0; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=6 COVID-19 Messaging for Vaccination
Vaccination Refusal · COVID-19 Pandemic
Primary: Changes in County-Level Covid-19 Vaccination Measured by Inverse Hyperbolic Sine — 0; -0.023; -0.007; -0.037 asinh(new dose 1s of vaccine)
N/A N=13 Metaplasticity Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change
Healthy
Primary: Percent Change in MEP Amplitude — 1.19; 1.06; 1.38 Percent Change
Phase 1 N=6 A Study of LY3337641 in Healthy Male Participants
Healthy
Primary: Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 2.9 Percentage of total dose
Phase 2 N=33 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · Vulvar Dysplasia · Vulvar Intraepithelial Neoplasia (VIN)
Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…
N/A N=253 Avoidance of Hyperglycaemia in People With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Hyperglycaemia Avoidance Scale — 44.6 score on a scale
Phase 2 N=48 Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
Hypoglycemia
Primary: Outpatient Phase: Incidence Rate of Hypoglycemia During and After Moderate to High Intensity Aerobic Exercise. — 0.12; 0.39; 0.16; 0.24 events/session — p=0.0002
N/A N=59 Identifying the Optimal Neural Target for Misophonia Interventions
Misophonia · Emotion Dysregulation
Primary: Physiological Outcome: High Frequency Heart Rate Variability (HF-HRV) Recorded During Experimental Blocks — 1.8903; 1.9422; 1.9420; 1.9465 lg(ms^2) — p=.221
Phase 1 N=36 A Study of LY3337641 in Japanese and Caucasian Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 2 N=23 Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model
Perinatal Depression · Post Partum Depression · Depression, Postpartum
Primary: Mean Threat Processing Bias During Visual Dot-probe Paradigm Over Time — -0.57; 36.92; -9.04; -42.35 attention bias in milliseconds — p=0.160
N/A N=147 Comparing KIM to TVT Exact Sling
Stress Urinary Incontinence
Primary: Number of Participants With Treatment Success at 6 Weeks After Surgery — 61; 51 Participants — p=0.04
Phase 4 N=64 Assessing Success of MTA and Pre-mixed Bioceramic in Mature Teeth With Irreversible Pulpitis With Full Pulpotomy.
Pulpitis - Irreversible
Primary: Clinical Success at 6 Months — 27; 30 Participants
Phase 3 N=1,594 Maximizing Outcomes in Treating Acute Migraine
Migraine
Primary: Percentage of Subjects Reporting Headache Pain Freedom — 85; 14 Participants — p=<0.001
Phase 2 N=21 Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
Narcolepsy · Cataplexy Narcolepsy · Excessive Sleepiness
Primary: Change From Baseline in the Weekly Average Total Number of Cataplexy Attacks — 13.0; -0.28 weekly cataplexy attacks — p=<0.001
N/A N=170 Agreement and Precision Study of the Nidek Mirante
Glaucoma · Retinal Disease · Corneal Disease
Primary: Agreement of Macular Thickness (μm) Measurement for Nidek Mirante and Optovue RTVue XR Avanti OCT — 10.658; 11.032; 11.415; 19.200 μm